Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Human Cancer Immunology and Cancer Vaccine Development

Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein

Weisan Chen, Heather Jackson, Nektaria Dimopoulos, Tsin Yee Tai, Nicole A. Mifsud, Qiyuan Chen, Lena Miloradovic, Eugene Maraskovsky, Lloyd J. Old, Ian D. Davis and Jonathan S. Cebon
Weisan Chen
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Jackson
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nektaria Dimopoulos
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsin Yee Tai
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole A. Mifsud
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiyuan Chen
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lena Miloradovic
2Ludwig Institute for Cancer Research, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene Maraskovsky
1Ludwig Institute for Cancer Research, Melbourne, Australia
3CSL Limited, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd J. Old
2Ludwig Institute for Cancer Research, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian D. Davis
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan S. Cebon
1Ludwig Institute for Cancer Research, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2005
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Antigen-specific CD8+ T cells can play an important role in the development of cancers through the process of immunoediting (1). Many cancer immunotherapy trials are based upon this rationale. Few clinical trials to date have achieved the ultimate goal of eliminating all cancer cells and cure of the disease. As a result, surrogate measurements are often used for monitoring trial outcomes. In order for an immunotherapy trial to be interpretable it is important that immunological monitoring be well characterized and validated.

Although peptide-based trials are relatively easy to conduct and monitor, overall their efficacy has been disappointing. Full-length tumor antigen based strategies are attracting more attention due to the integration of T cell help, which is essential for both cytotoxic T lymphocyte (CTL) priming and recall phase expansion. Full length protein also provides the opportunity for the host antigen presenting cells to process relevant immunodominant epitopes. However, monitoring of vaccinated T-cell responses remains challenging, particularly if the key epitopes have not been defined, or if there are responses to multiple determinants.

NY-ESO-1 is an immunogenic but relatively small (180 amino acids) "cancer-testis" antigen. We have evaluated cellular immune responses in two patient populations; (i) a series of melanoma patients whose tumors expressed the NY-ESO-1 antigen and in whom spontaneous immune responses developed during the course of their disease, (ii) patients who were vaccinated with recombinant full-length NY-ESO-1 protein produced in a bacterial expression system and formulated with ISCOMATRIX™ adjuvant (NY-ESO-1/IMX) (LUD99-008) in collaboration with CSL Limited (2, 3, 4). Only limited HLA serotyping data were available for the trial participants. Without knowledge of the potential CD8+ and CD4+ T-cell epitopes for each individual patient, we developed a robust method for in vitro T-cell expansion and systematically monitored T-cell responses from both vaccinated patients and patients who had shown naturally induced anti-NY-ESO-1 antibody responses. Utilizing multiple sets of synthetic overlapping peptides as well as various sources of full-length NY-ESO-1 protein, very broad T-cell responses to NY-ESO-1 epitopes have been identified, including previously known and unknown ones. We were also able to demonstrate that the majority of the detected CD8+ and CD4+ T-cell responses were induced by vaccination with NY-ESO-1/IMX, because the same responses were not detected from pre-vaccination samples of the same patients. Some NY-ESO-1-specific T cells were primed after the first vaccination and boosted subsequently. We also detected polyclonal CD8+ and CD4+ T-cell responses against multiple epitopes from naturally induced NY-ESO-1-specific responses from some patients with serum antibody to NY-ESO-1. The NY-ESO-1 sequence 79-110 contains an epitope-rich area for vaccinated patients despite only limited sharing of HLA alleles. Analysis of T-cell responses specific to this region of the NY-ESO-1 antigen might serve as a quick screening strategy for both naturally induced and vaccinated immunity. Under similar monitoring conditions, no NY-ESO-1-specific response was detected for samples collected from normal individuals.

This kind of detailed T-cell analysis will not only help us to further understand the scope, efficacy and the immunodominance hierarchy of both natural and vaccinated anti-tumor cellular immune responses, but also help us to identify the most immunodominant T helper and cytotoxic T-cell epitopes. This in turn may be very important for future vaccine development and more efficient trial monitoring.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

 

  • Copyright © 2005 by Weisan Chen

References

  1. 1.
    1. Dunn GP,
    2. Bruce AT,
    3. Ikeda H,
    4. Old LJ,
    5. Schreiber RD
    . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–8.pmid:12407406
    OpenUrlCrossRefPubMed
  2. 2.
    1. Davis ID,
    2. Chen W,
    3. Jackson H,
    4. Parente P,
    5. Shackleton M,
    6. Hopkins W,
    7. Chen Q,
    8. Dimopoulos N,
    9. Luke T,
    10. Murphy R,
    11. Scott AM,
    12. Maraskovsky E,
    13. McArthur G,
    14. MacGregor D,
    15. Sturrock S,
    16. Tai TY,
    17. Green S,
    18. Cuthbertson A,
    19. Maher D,
    20. Miloradovic L,
    21. Mitchell SV,
    22. Ritter G,
    23. Jungbluth AA,
    24. Chen YT,
    25. Gnjatic S,
    26. Hoffman EW,
    27. Old LJ,
    28. Cebon JS
    . Recombinant NY-ESO-1 protein with IS-COMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T-cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697–702.pmid:15252201
    OpenUrlAbstract/FREE Full Text
  3. 3.
    1. Chen Q,
    2. Jackson H,
    3. Parente P,
    4. Luke T,
    5. Rizkalla M,
    6. Tai TY,
    7. Zhu HC,
    8. Mifsud NA,
    9. Dimopoulos N,
    10. Masterman KA,
    11. Hopkins W,
    12. Goldie H,
    13. Maraskovsky E,
    14. Green S,
    15. Miloradovic L,
    16. McCluskey J,
    17. Old LJ,
    18. Davis ID,
    19. Cebon J,
    20. Chen W
    . Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A 2004;101:9363–8.pmid:15197261
    OpenUrlAbstract/FREE Full Text
  4. 4.
    1. Jackson HM,
    2. Dimopoulos N,
    3. Chen Q,
    4. Luke T,
    5. Yee Tai T,
    6. Maraskovsky E,
    7. Old LJ,
    8. Davis ID,
    9. Cebon J,
    10. Chen W
    . A robust human T cell culture method suitable for expanding tumor specific CD8+ and CD4+ T cells to known and unknown epitopes. J Immunol Methods 2004;291:51–62.pmid:15345304
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Immunity Archive: 5 (Suppl 1)
January 2005
Volume 5, Issue Suppl 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein
Weisan Chen, Heather Jackson, Nektaria Dimopoulos, Tsin Yee Tai, Nicole A. Mifsud, Qiyuan Chen, Lena Miloradovic, Eugene Maraskovsky, Lloyd J. Old, Ian D. Davis and Jonathan S. Cebon
Cancer Immun January 1 2005 (5) (Suppl 1) 14;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein
Weisan Chen, Heather Jackson, Nektaria Dimopoulos, Tsin Yee Tai, Nicole A. Mifsud, Qiyuan Chen, Lena Miloradovic, Eugene Maraskovsky, Lloyd J. Old, Ian D. Davis and Jonathan S. Cebon
Cancer Immun January 1 2005 (5) (Suppl 1) 14;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Vaccine strategies against NY-ESO-1 in cancer patients
  • Tumor-specific T cells induced in melanoma patients either naturally or by vaccination with peptides, IFA ± CpG oligodeoxynucleotides
  • NY-ESO-1 protein-based cancer vaccines: the Melbourne experience
Show more Human Cancer Immunology and Cancer Vaccine Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement